| 0.03 -0 (-0%) | 07-23 09:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
FOXO Technologies Inc. operates as a technology platform company primarily focused on translating longevity science into practical applications for the life insurance sector. The firm is actively creating products and services that integrate scientific understanding of longevity with life insurance offerings. The dual objectives of these innovations are to encourage greater consumer involvement in their health and wellness, and to streamline the often-complex insurance underwriting process for customers. Among its key offerings is FOXO Labs, a service-oriented platform that enhances the customer underwriting experience by incorporating saliva-based epigenetic biomarkers into expedited underwriting procedures. Additionally, the company provides FOXO Life, an insurance products platform. This platform offers a combination of FOXO's own unique life insurance products and policies from third-party carriers, all designed to bundle longevity science with life insurance. FOXO Technologies Inc. was established in 2019 and is headquartered in Minneapolis, Minnesota.
Wed, 01 Jul 2026
FOXO Technologies Inc Warrant 2022- For shares FOXO Tech Rg Financial Disclosures & SEC Filings - TradingView
Wed, 01 Jul 2026
FOXO Technologies completes 1-for-3,000 reverse stock split to boost share price and attract investors. - Pluang
Wed, 01 Jul 2026
FOXO TECHNOLOGIES INC. ANNOUNCES COMPLETION OF REVERSE STOCK SPLIT - GlobeNewswire
Tue, 23 Jun 2026
FOXO licenses its epigenetics tech back to the founder it fired - Coverager
Wed, 17 Jun 2026
Foxo Technologies Inc (FOXO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Thu, 28 May 2026
FOXO partners with LongevityFP to commercialize epigenetics tech with royalty and equity deal - Pluang
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|